Abstract
Inflammatory bowel disease (IBD) is an inflammatory disease of the gastrointestinal tract with complex pathogenesis. Here, we synthesized 6-heteroarylamino analogues to inhibit TNF-α-induced adhesion of monocytes to colon epithelial cells which are implicated in the initial inflammation process of IBD. The best analogue, 16a, showed IC50 = 0.29 μM, which is about five orders of magnitude better than that of 5-aminosalicylic acid (5-ASA), a positive control. Oral administration of 6f and 16a dramatically ameliorated 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colon inflammation in rat. The ameliorating effects were accompanied by a high level of recovery in colon and body weights and in the myeloperoxidase (MPO) level. Consistently, the compounds suppressed the expression of intercellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant protein 1 (MCP-1). Moreover, they significantly suppressed the expression of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 while increasing the level of IL-10, an anti-inflammatory cytokine.
References
Jun 1, 1990·Gut·M LigumskyD Rachmilewitz
Dec 1, 1988·Gastroenterology·E SekizukaD N Granger
Feb 1, 1997·Clinical and Experimental Immunology·G KojouharoffW Falk
Sep 24, 2004·Journal of Pharmacological and Toxicological Methods·Abdo R JurjusJean-Marie Reimund
Sep 1, 2005·Clinical Reviews in Allergy & Immunology·Raja Atreya, Markus F Neurath
Dec 24, 2005·The Journal of Pharmacology and Experimental Therapeutics·Naoki KobayashiTeruna J Siahaan
Nov 1, 2006·Inflammatory Bowel Diseases·Torsten KucharzikWolfram Domschke
Apr 22, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kevin N CouperEleanor M Riley
Aug 30, 2008·The Journal of Pharmacology and Experimental Therapeutics·Dinesh ThapaJung-Ae Kim
Jun 17, 2011·Nature·Bernard KhorRamnik J Xavier
Jan 13, 2012·Annals of the New York Academy of Sciences·Erik-Oliver GlockerBodo Grimbacher
Aug 15, 2012·The Journal of Experimental Medicine·Margherita CocciaKevin J Maloy
Dec 12, 2012·The Journal of Organic Chemistry·Seung-Ju YangYoung-Dae Gong
Aug 1, 2013·Inflammatory Bowel Diseases·David J GibsonGlen A Doherty
Oct 10, 2013·Current Drug Targets·Mariangela AlloccaSilvio Danese
Feb 1, 2014·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·William J SandbornUNKNOWN Study A3921043 Investigators
Apr 1, 2014·European Journal of Medicinal Chemistry·Dong-Guk KimByeong-Seon Jeong
Apr 29, 2014·Bioorganic & Medicinal Chemistry·Nobuhiko HayakawaTakashi Yamamoto
Apr 29, 2014·European Journal of Pharmacology·Sumin ParkJung-Ae Kim
Jun 19, 2014·Bioorganic & Medicinal Chemistry·Koichi HasumiShuji Ohta
Dec 23, 2014·Digestive Diseases·Bruce E Sands
Mar 19, 2015·The New England Journal of Medicine·Giovanni MonteleoneFrancesco Pallone
Aug 26, 2015·The American Journal of Gastroenterology·L Peyrin-BirouletJ-F Colombel
Sep 2, 2015·Nature Reviews. Gastroenterology & Hepatology·Gilaad G Kaplan
Dec 22, 2015·Current Opinion in Pharmacology·Ivana BravatàSilvio Danese
Jan 26, 2016·Pharmacology & Therapeutics·Caroline Meyer OlesenOle Haagen Nielsen
Sep 7, 2016·Bioorganic & Medicinal Chemistry Letters·Suhrid BanskotaTae-Gyu Nam
Feb 2, 2017·Nature Reviews. Gastroenterology & Hepatology·Markus F Neurath
Citations
Feb 5, 2019·Advanced Healthcare Materials·Bingchao DuanXiaojuan Xu
Oct 18, 2019·Journal of Enzyme Inhibition and Medicinal Chemistry·Chhabi Lal ChaudharyByeong-Seon Jeong
Aug 4, 2020·Bioorganic Chemistry·Chhabi Lal ChaudharyByeong-Seon Jeong
Aug 21, 2018·Chemico-biological Interactions·Jaya GautamJung-Ae Kim
Apr 26, 2021·Bioorganic & Medicinal Chemistry Letters·Ujjwala KarmacharyaByeong-Seon Jeong
Aug 4, 2021·Journal of Enzyme Inhibition and Medicinal Chemistry·Bhuwan Prasad AwasthiByeong-Seon Jeong